United Statesbreakthroughproperties.com
Its role Developer
Breakthrough Properties is a life sciences real estate company that develops, acquires, and operates laboratory and office facilities for biotechnology and pharmaceutical research. Formed as a joint venture between Tishman Speyer and Bellco Capital, the firm focuses on providing modern wet-lab and related R&D environments suited to companies across the drug discovery and development spectrum.
The company concentrates its portfolio in leading innovation hubs in the United States and Europe, delivering multi-tenant labs, incubator-ready space, and build-to-suit campuses. Its properties serve tenants ranging from early-stage ventures to established biopharma organizations, supporting activities in chemistry, biology, and translational research.
chemXplore tracks 1 project involving Breakthrough Properties.
Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.
Allston hub will focus on cardiovascular, renal and metabolic R&D, combine discovery-to-clinical work with AI and data science, and is part of a USD 50bn US investment programme.
New site in Philadelphia will provide lab space and support for early-stage biotech firms, enhancing Lilly's presence in key innovation hubs.
active all projects
